XML 47 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2012
Acquisitions [Abstract]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
Cash
$
227.9

Accounts Receivable
451.4

Other Current Assets
166.2

Property, Plant & Equipment
11,755.0

Intangibles
5,700.0

Goodwill
7,013.5

Other Assets
581.9

Accounts Payable
1,370.9

Other Liabilities
540.5

Amount Due Related Party
3,000.0

Mortgages Payable
3,784.6

The fair value of assets acquired and liabilities assumed on October 17, 2011 is as follows (in thousands):
 
Cash
$
92.9

Prepaid Expenses
178.2

In Process R&D
9,400.0

Goodwill
4,104.5

Accounts Payable & Accrued Liabilities
1,177.1

Deferred Tax Liability
3,774.7

Amount Due Related Party
340.4
Schedule Of Consolidated Proforma Financial Information [Table Text Block]
acquisitions of Amorcyte and PCT had occurred on January 1, 2010 (in thousands, except per share amounts):

 
 
Year Ended December 31,
  
 
2011
 
2011
  
 
(As Reported)
 
(Pro Forma)
 
 
 
 
 
Revenues
 
$
10,050

 
$
10,322

Cost of revenues
 
8,647

 
8,923

Gross profit
 
1,403

 
1,400

Research and development
 
7,721

 
7,964

Selling, general, and administrative
 
27,687

 
29,473

Operating loss
 
(34,005
)
 
(36,037
)
Other expense, net
 
(562
)
 
(548
)
Net loss from continuing operations
 
(34,566
)
 
(36,586
)
Loss from discontinued operations - net
 
(22,017
)
 
(22,017
)
Net loss
 
(56,583
)
 
(58,602
)
Less – net income attributable to noncontrolling interests
 
(9,448
)
 
(9,448
)
Preferred dividends
 
640

 
640

Net loss attributable to NeoStem, Inc. common stockholders
 
$
(47,774
)
 
$
(49,794
)
Basic and diluted loss per share
 
$
(0.54
)
 
$
(0.53
)
Weighted average common shares outstanding
 
88,599

 
93,793